clipboard

We offer 1800+ tests in clinical, molecular and anatomic pathology.

FIND A TEST
Doctor

With over 18 subspecialties and 60+ experts, we can help with even the most difficult cases. 

GET STARTED
Blood Draw

Visit one of our 21 blood draw locations today.

SEARCH NOW

NEWS & EVENTS

February 1, 2021

Ranked Top 10 Global University for Oncology Research

U-M was recently ranked No. 9 among institutions globally in cancer research, according to the U.S. News & World Report 2021 Best Global University Rankings.

January 20, 2021

New Test: DDIT3 (12q13) Rearrangement by FISH

The detection of DDIT3 rearrangements can be useful in diagnosing myxoid liposarcoma – including uncommon histologic variants – and in distinguishing this sarcoma from other mesenchymal tumors that may be considered in the differential diagnosis.

January 5, 2021

Michigan Medicine named one of The Best and Brightest Companies to Work For

Michigan Medicine named The Best and Brightest Companies to Work For®. A competition that identifies and honors organizations that display a commitment to excellence in their human resource practices and employee enrichment. 

SEE ALL NEWS

Featured Test (NEW)

 

PD-L1 Testing for Breast Cancer

Now offering PD-L1 testing using SP142, the FDA-approved companion diagnostic for TECENTRIQ in mTNBC.  FDA-approval to evaluate triple-negative breast cancer patients, VENTANA PD-L1 (SP142) Assay uses immune cell staining and scoring within the tumor microenvironment. 


LEARN MORE

PDL-1 Testing for Breast Cancer

Featured Test (NEW)

 

Myeloid NGS Panel

This test is intended for the molecular evaluation of myeloid neoplasms including myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS), myelodysplastic/myeloproliferative neoplasms, acute myeloid leukemias (AML), mastocytosis and myeloid neoplasms with eosinophilia and gene rearrangement.


LEARN MORE

Senior woman thinking

Featured Test

 

NGS Solid Tumor Panel


Molecular testing of solid tumor neoplasms - particularly advanced-stage cancer. This DNA and RNA based, NGS test targets 50 actionable genes (35 mutations, 19 amplifications, 21 - fusions). Requires <1mm2 of tissue (as little as 100 tumor cells) and a low 3% QNS rate. 

 

LEARN MORE

Patient Older Woman Gown

Featured Test

 

FGFR Mutation/Translocation


Erdafitinib (Balversa™) is an FGFR-inhibitor that is FDA-approved for the treatment of metastatic urothelial cancers harboring susceptible mutations or translocations involving FGFR2 or FGFR3. 
 

LEARN MORE

NCRC Staff

Featured Test

 

NR4A3 (9q22-9q31) Rearrangement (FISH)

NR4A3 encodes an orphan nuclear receptor. Rearrangements of NR4A3 occur in more than 80% of extraskeletal myxoid chondrosarcoma (EMC) as well as in salivary acinic cell carcinoma (AciCC), driving tumorigenesis. 


LEARN MORE

Dr Brown

Featured Test

 

PIK3CA Mutation: 

NEW TREATMENT OPTION FOR METASTATIC BREAST CANCER

MLabs offers NGS Solid Tumor Panel and Single gene test to detect PIK3CA for FDA approved therapy alpelisib (Piqray®).


LEARN MORE
 

Older Woman and Girl Hugging Beach

Featured Test

 

TFE3 Rearrangement (FISH)

 Detecting rearrangements involving the TFE3 gene region (Xp11.2) via fluorescence in situ hybridization (FISH) to qualitatively assess for the presence of TFE3 translocations that are associated with certain subtypes of renal cell carcinoma. Testing for TFE3 gene rearrangement may aid in the diagnosis and classification of renal tumors.


LEARN MORE

NCRC Staff